Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Endostatin gene transfection using a cationic lipid: advantages of transfection before tumor cell inoculation and repeated transfection

Cancer Gene Therapy volume 11, pages 354–362 (2004)Cite this article

Abstract

Intravenous endostatin gene transfection results in tumor suppression in a murine pulmonary metastasis model. We transfected the endostatin gene at different times, in order to achieve an optimal protective effect. pST2-Endo encoding murine endostatin was injected in a complex with cationic lipid. Pulmonary metastases were caused by intravenous injection of murine fibrosarcoma cells. Mice were observed for 14 days following fibrosarcoma cell inoculation (FSI). In the study groups, the animals were transfected with pST2-Endo at three different times: 2 days before and 3 and 7 days after FSI. In the group transfected with pST2-Endo 2 days before FSI, the weights of the lungs and tumor-occupied area ratio were significantly less than in the other groups. Significant inhibition of tumor neovascularization was documented by means of CD31 immunohistochemistry. The effect of repeated endostatin transfection on survival after FSI was determined. Animals repeatedly transfected with the endostatin gene survived significantly longer than the groups treated with a single endostatin gene transfection. A stable endostatin-expressing fibrosarcoma transfectant was created and tested for migration and invasion. Compared with controls, endostatin expression reduced migration and invasion by 15%. It is concluded that endostation gene transfection before FSI and repeated transfection thereafter results in significant tumor suppression.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7

Similar content being viewed by others

References

  1. Folkman J . Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1995;1:27–31.

    Article  CAS  PubMed  Google Scholar 

  2. Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353–364.

    Article  CAS  PubMed  Google Scholar 

  3. Boehm T, Folkman J, Browder T, O'Reilly MS . Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature. 1997;390:404–407.

    Article  CAS  PubMed  Google Scholar 

  4. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88:277–285.

    Article  CAS  PubMed  Google Scholar 

  5. Yamaguchi N, Anand-Apte B, Lee M, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independently of zinc binding. EMBO J. 1999;18:4414–4423.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Hanai J, Dhanabal M, Karumanchi SA, et al. Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem. 2002;277:16464–16469.

    Article  CAS  PubMed  Google Scholar 

  7. Putney SD, Burke PA . Improving protein therapeutics with sustained-release formulations. Nat Biotechnol. 1998;16:153–157.

    Article  CAS  PubMed  Google Scholar 

  8. Crystal RG . The body as a manufacturer of endostatin. Nat Biotechnol. 1999;17:336–337.

    Article  CAS  PubMed  Google Scholar 

  9. Kisker O, Becker CM, Prox D, et al. Continuous administration of endostatin by intraperitoneally implanted osmotic pump improves the efficacy and potency of therapy in a mouse xenograft tumor model. Cancer Res. 2001;61:7669–7674.

    CAS  PubMed  Google Scholar 

  10. Nakashima Y, Yano M, Kobayashi Y, et al. Endostatin gene therapy on murine lung metastases model utilizing cationic vector-mediated intravenous gene delivery. Gene Therapy. 2003;10:123–130.

    Article  CAS  PubMed  Google Scholar 

  11. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D . Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 1999;284:808–812.

    Article  CAS  PubMed  Google Scholar 

  12. DeLisser HM, Christofidou-Solomidou M, Strieter RM, et al. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol. 1997;151:671–677.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. Yew NS, Wysokenski DM, Wang KX, et al. Optimization of plasmid vectors for high-level expression in lung epithelial cells. Hum Gene Ther. 1997;8:575–584.

    Article  CAS  PubMed  Google Scholar 

  14. Song YK, Liu F, Chu S, Liu D . Characterization of cationic liposome-mediated gene transfer in vivo by intravenous administration. Hum Gene Ther. 1997;8:1585–1594.

    Article  CAS  PubMed  Google Scholar 

  15. Sauter BV, Martinet O, Zhang WJ, Mandeli J, Woo SL . Adenovirus-mediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases. Proc Natl Acad Sci USA. 2000;97:4802–4807.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Jin X, Bookstein R, Wills K, et al. Evaluation of endostatin antiangiogenesis gene therapy in vitro and in vivo. Cancer Gene Ther. 2001;8:982–989.

    Article  CAS  PubMed  Google Scholar 

  17. Marshall E . Cancer therapy. Setbacks for endostatin. Science. 2002;295:2198–2199.

    Article  CAS  PubMed  Google Scholar 

  18. Yew NS, Wang KX, Przybylska M, et al. Contribution of plasmid DNA to inflammation in the lung after administration of cationic lipid:pDNA complexes. Hum Gene Ther. 1999;10:223–234.

    Article  CAS  PubMed  Google Scholar 

  19. Whitmore MM, Li S, Falo Jr L, Huang L . Systemic administration of LPD prepared with CpG oligonucleotides inhibits the growth of established pulmonary metastases by stimulating innate and acquired antitumor immune responses. Cancer Immunol Immunother. 2001;50:503–514.

    Article  CAS  PubMed  Google Scholar 

  20. Mundhenke C, Thomas JP, Wilding G, et al. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clin Cancer Res. 2001;7:3366–3374.

    CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We gratefully acknowledge Dr Koichi Ando (National Institute of Radiological Sciences, Chiba, Japan) for providing the murine fibrosarcoma cell line NFSa Y83. We thank Ms A Miyazaki, Ms M Nishio, and Ms S Makino for technical assistance.

Author information

Authors and Affiliations

  1. Department of Surgery II, Nagoya City University Medical School, Mizuho-ku, Nagoya, 467-8601, Japan

    Motoki Yano, Yoshiaki Nakashima, Yoshihiro Kobayashi, Kotaro Mizuno, Akimitsu Konishi, Hidefumi Sasaki, Ichiro Fukai & Yoshitaka Fujii

  2. Genzyme Corporation, Framingham, Massachusetts, USA

    Ronald K Scheule

Authors
  1. Motoki Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yoshiaki Nakashima
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yoshihiro Kobayashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Kotaro Mizuno
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Akimitsu Konishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hidefumi Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ichiro Fukai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Ronald K Scheule
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yoshitaka Fujii
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Motoki Yano.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yano, M., Nakashima, Y., Kobayashi, Y. et al. Endostatin gene transfection using a cationic lipid: advantages of transfection before tumor cell inoculation and repeated transfection. Cancer Gene Ther 11, 354–362 (2004). https://doi.org/10.1038/sj.cgt.7700704

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.cgt.7700704

Keywords

This article is cited by

Search

Advanced search

Quick links